{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-058666","form_type":"8-K","ticker":"CHRS","cik":"0001512762","company_name":"Coherus Oncology, Inc.","filed_at":"2026-05-11T20:16:20+00:00","discovered_at":"2026-05-11T20:18:00.308484+00:00","generated_at":"2026-05-11T22:08:11.083381+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Coherus Q1 LOQTORZI rev $11.8M (+61% YoY); net loss $36.9M; pipeline readouts mid-2026","bullets":["LOQTORZI net revenue $11.8M in Q1 2026, up 61% YoY from $7.3M but down 5% from Q4 2025 $12.4M due to weather and seasonality.","GAAP net loss from continuing ops $36.9M ($(0.27) diluted EPS) vs $47.4M ($(0.41)) in Q1 2025; non-GAAP net loss $33.9M ($(0.25)).","Cash, cash equivalents and marketable securities $167.0M; Q1 equity offering of 32.89M shares raised net proceeds of $53.6M.","Casdozokitug Phase 2 1L HCC fully enrolled, first data readout expected mid-2026; tagmokitug combo studies with initial data mid-2026 and 2H 2026.","Q1 recorded highest new patient starts for LOQTORZI; average treatment duration growing; LOQTORZI remains only FDA-approved treatment for NPC."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-058666","json":"https://secwatch.observer/filing/0001104659-26-058666.json","markdown":"https://secwatch.observer/filing/0001104659-26-058666.md","text":"https://secwatch.observer/filing/0001104659-26-058666.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1512762/000110465926058666/0001104659-26-058666-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1512762/000110465926058666/chrs-20260511x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-11T22:08:11.083381+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c8ae5259cbfc2843e6187a8ded6154814e9e2c79","claim":"Coherus Oncology, Inc. reported financial results for first quarter 2026.","evidence_excerpt":"On May 11, 2026, Coherus Oncology, Inc. (the “Company”) issued a press release regarding its financial results for the quarter ended March 31, 2026.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1512762/000110465926058666/0001104659-26-058666-index.htm","confidence":0.92,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter 2026"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}